Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live attenuated varicella vaccine (China National Biotec Group)
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This is a live attenuated varicella vaccine developed by the China National Biotec Group (CNBG), specifically through its subsidiary, the Beijing Institute of Biological Products. The vaccine is designed to prevent varicella (chickenpox) infection caused by the varicella-zoster virus (VZV). It is likely based on the internationally recognized Oka strain, which is the standard for most live attenuated varicella vaccines. The vaccine has undergone Phase III clinical trials (e.g., NCT05443490 and NCT05443503) to evaluate its efficacy, safety, and immunogenicity in healthy children aged 1 to 12 years, with additional safety lead-in studies in individuals aged 13 to 59 years. It is administered as a 0.5 ml injection and works by inducing active immunity against the virus.
- Other names
- CNBG varicella vaccineBeijing Institute varicella vaccineInvestigational live attenuated varicella vaccine
Beyond the preview
Go deeper on live attenuated varicella vaccine (China National Biotec Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live attenuated varicella vaccine (China National Biotec Group).